Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest update is out from Ascentage Pharma Group International ( (HK:6855) ).
Ascentage Pharma Group International has successfully completed the placement of 22 million existing shares and a top-up subscription of 22 million new shares, raising approximately HK$1,492.5 million. The proceeds will be used to enhance commercialization efforts, advance global clinical development, and strengthen infrastructure and working capital, thereby positioning the company for growth in its core therapeutic areas.
The most recent analyst rating on (HK:6855) stock is a Buy with a HK$40.00 price target. To see the full list of analyst forecasts on Ascentage Pharma Group International stock, see the HK:6855 Stock Forecast page.
More about Ascentage Pharma Group International
Ascentage Pharma Group International is a biopharmaceutical company focused on developing therapies for cancers, chronic hepatitis B, and age-related diseases. The company is committed to advancing its core pipeline candidates and expanding its market reach globally.
Average Trading Volume: 5,378,819
Technical Sentiment Signal: Buy
Current Market Cap: HK$26.97B
For detailed information about 6855 stock, go to TipRanks’ Stock Analysis page.